Cardiac stem cells from young hearts can make older hearts young, study says – News-Medical.net
News-Medical.net |
Cardiac stem cells from young hearts can make older hearts young, study says
News-Medical.net Eduardo Marbán, MD, PhD, director of the Cedars-Sinai Heart Institute and the primary investigator of the study said, according to their previous lab studies as well as human clinical trials, cardiac stem cell infusions were seen to be effective in … Older hearts could be rejuvenated with stem cells from younger ones – studyRT New Study Reveals Stem Cells from Young Hearts May Help Reverse the Aging ProcessFuturism Could Newborn Heart Stem Cells Jump-Start Old Hearts?Arizona Daily Star FOX31 Denver –The Nation all 10 news articles » |
|
Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography – Trends, Analysis …
Medgadget (blog) Over the last few years, CAR T Cell therapy has gained wide recognition in the healthcare industry. CAR T cell is an innovative technique that involves removal of T Cells from patient’s blood before reinsertion using a genetically altered mechanism. |
Futurism |
CRISPR–Cas becoming more human
Nature.com In the past few years, the CRISPR–Cas technology has been developed to precisely edit genomic DNA; so far, these approaches have been used mainly in cultured cells or in animal embryo models, but only a few studies have reported their use in human … New CRISPR technique could accelerate a cure for Huntington’s …Digital Trends A New Gene Editing Technique Could Finally Allow Us to Treat ALSFuturism |
|
Gene Therapy and Antisense Drugs Market Scope and Revenue Outlook For Forecast to 2025
Medgadget (blog) Since an escalating number of patients are being diagnosed with cancer every day, the global demand for gene therapy and antisense drugs is bound to multiply. The growing incidence of health conditions such as Parkinson’s disease and high cholesterol … |
|
CAR T-Cell Therapies for Hematologic Malignancies Moving Toward the Clinic
Targeted Oncology Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refrac- tory acute lymphoblastic leukemia (R/R ALL). J Clin Oncol. 2017;35(suppl; abstr 3024). Locke FL … Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography – Trends, Analysis …Medgadget (blog) |